<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02306291</url>
  </required_header>
  <id_info>
    <org_study_id>GMI-1271-201</org_study_id>
    <nct_id>NCT02306291</nct_id>
  </id_info>
  <brief_title>Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML</brief_title>
  <official_title>A Phase I/II, Open-label Multicenter Trial to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in Patients With Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlycoMimetics Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlycoMimetics Incorporated</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate GMI-1271, a specific E-selectin antagonist, in acute myeloid
      leukemia in combination with standard agents used to treat this disease.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety assessed by frequency, severity and relatedness of adverse events</measure>
    <time_frame>up to 44 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time versus plasma concentration profile of GMI-1271</measure>
    <time_frame>up to 11 days</time_frame>
    <description>Plasma concentration of GMI-1271</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Proportion of subjects who achieve a complete response (CR) or CR with incomplete blood count recovery (CRi) per local investigator assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Time from date of first dose to first documentation of response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Time from date of first documented remission to the date of relapse or death from any cause, whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Time from date of first dose to the date of treatment failure, relapse, or death from any cause, whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>up to 12 months</time_frame>
    <description>The probability of survival at 6 months (Phase 1) and 12 months (Phase 2), after the date of first dose of study drug</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">91</enrollment>
  <condition>Leukemia, Myeloid, Acute</condition>
  <arm_group>
    <arm_group_label>Arm A (Phase I)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GMI-1271 in combination with mitoxantrone, etoposide and cytarabine (MEC) in relapsed/refractory subjects 18 years and older</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (Phase II Arm A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GMI-1271 in combination with mitoxantrone, etoposide and cytarabine (MEC) in relapsed/refractory subjects 18 years and older</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C (Phase II Arm B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GMI-1271 in combination with cytarabine and idarubicin (7+3 regimen) in newly diagnosed subjects 60 years and older</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GMI-1271</intervention_name>
    <description>Dose escalation</description>
    <arm_group_label>Arm A (Phase I)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GMI-1271</intervention_name>
    <description>Dose expansion</description>
    <arm_group_label>Arm B (Phase II Arm A)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GMI-1271</intervention_name>
    <description>Safety run-in then dose expansion</description>
    <arm_group_label>Arm C (Phase II Arm B)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. AML (including secondary AML) diagnosed as per WHO criteria

          2. For relapsed/refractory subjects only:

               -  Subjects age ≥ 18 years with relapsed or refractory AML after ≤ 2 prior induction
                  regimens, at least one containing anthracyclines

               -  Medically eligible to receive MEC

               -  Absolute blast count (ABC) ≤ 40,000/mm

          3. For treatment-naïve subjects only:

               -  Subjects ≥ 60 years of age with newly diagnosed AML

               -  Medically eligible to receive &quot;7+3&quot; cytarabine/idarubicin

               -  ABC count ≤ 40,000/mm

          4. ECOG performance status 0-2

          5. Hemodynamically stable and adequate organ function

        Exclusion criteria:

          1. Acute promyelocytic leukemia

          2. Acute leukemia of ambiguous lineage (biphenotypic leukemia)

          3. Active signs or symptoms of CNS involvement by malignancy

          4. No prior G-CSF, GM-CSF or plerixafor within 14 days of study drug dosing

          5. Known history or evidence of active hepatitis A, B, or C or HIV

          6. Uncontrolled acute life threatening bacterial, viral or fungal infection

          7. Active graft versus host disease (GVHD) ≥ Grade 2 or extensive chronic GVHD requiring
             immunosuppressive therapy

          8. Hematopoietic stem cell transplantation ≤ 4 months of dosing

          9. Clinically significant cardiovascular disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel DeAngelo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, Davis Comprehensive Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan, Ann Arbor</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Brisbane</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Galway</name>
      <address>
        <city>Galway</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Ireland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2014</study_first_submitted>
  <study_first_submitted_qc>December 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2014</study_first_posted>
  <last_update_submitted>October 26, 2017</last_update_submitted>
  <last_update_submitted_qc>October 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AML</keyword>
  <keyword>Acute myeloid leukemia</keyword>
  <keyword>E-selectin</keyword>
  <keyword>relapse refractory</keyword>
  <keyword>elderly newly diagnosed</keyword>
  <keyword>induction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

